Dual Blockade of the Renin–Angiotensin–Aldosterone System: Benefits Versus Adverse Outcomes

@inproceedings{Lattanzio2012DualBO,
  title={Dual Blockade of the Renin–Angiotensin–Aldosterone System: Benefits Versus Adverse Outcomes},
  author={Michael R. Lattanzio and MatthewR. Weir},
  year={2012}
}
Renin–angiotensin–aldosterone system (RAAS) blockade in patients with established heart or kidney disease provides an approximate 20 % relative risk reduction of disease progression, and cardiovascular (CV) or renal end points. There is minimal risk associated with this approach, especially with close monitoring. Whether dual RAAS blockade can provide incremental clinical benefit is of some debate. Overall, there is no CV benefit. However, dual RAAS blockade has not been well tested in patients… CONTINUE READING

Topics from this paper.

Similar Papers

Loading similar papers…